Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist

被引:30
作者
Shimatani, T
Inoue, M
Kuroiwa, T
Horikawa, Y
Mieno, H
Nakamura, M
机构
[1] Hiroshima Univ Hosp, Dept Gen Med, Minami Ku, Hiroshima 7348551, Japan
[2] Hiroshima Univ, Sch Med, Inst Hlth Sci, Dept Community & Geriatr Nursing, Hiroshima, Japan
[3] Med Co Kouwakai Eastern Examinat Ctr, Dept Internal Med, Hiroshima, Japan
[4] Hiroshima Railway Hosp, Dept Internal Med, Hiroshima, Japan
[5] Wakasagi Med Clin, Dept Internal Med, Tokyo, Japan
关键词
D O I
10.1046/j.1365-2036.2003.01804.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Omeprazole 10 mg is used as maintenance therapy for gastro-oesophageal reflux disease, but previous reports have not mentioned the potency of its acid suppression. Aim: To evaluate the potency of acid suppression with omeprazole 10 mg, in relation to CYP2C19 genotypes. Methods: Eighteen healthy subjects without Helicobacter pylori participated. After a 7-day regimen of omeprazole 10 mg, 20 mg, lafutidine 20 mg (a novel H-2-receptor antagonist) or water only (baseline data), intragastric pH was measured for 24 h. Results: With omeprazole 10 mg, greater differences were observed than 20 mg in median pH values and pH > 4 holding time ratios between poor metabolizers (PMs, n = 6) and the others [homozygous extensive metabolizers (homo-EMs, n = 6) and heterozygous extensive metabolizers (hetero-EMs, n = 6)]. With lafutidine 20 mg, these parameters were not influenced by the genotype. The potency of acid suppression was: omeprazole 20 mg approximate to lafutidine 20 mg > omeprazole 10 mg in homo-EMs, omeprazole 20 mg > omeprazole 10 mg approximate to lafutidine 20 mg in hetero-EMs, and omeprazole 20 mg approximate to omeprazole 10 mg > lafutidine 20 mg in PMs. Conclusions: Omeprazole 10 mg strongly suppresses acid secretion, but depending on the CYP2C19 genotypes shows greater interindividual variations in suppression than 20 mg.
引用
收藏
页码:1149 / 1157
页数:9
相关论文
共 53 条
  • [1] Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis
    Adachi, K
    Fujishiro, H
    Katsube, T
    Yuki, M
    Ono, M
    Kawamura, A
    Rumi, MAK
    Watanabe, M
    Kinoshita, Y
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (11) : 1191 - 1196
  • [2] Pharmacokinetics, metabolism and interactions of acid pump inhibitors - Focus on omeprazole, lansoprazole and pantoprazole
    Andersson, T
    [J]. CLINICAL PHARMACOKINETICS, 1996, 31 (01) : 9 - 28
  • [3] CLINICAL-STUDY ON THE PATHOPHYSIOLOGY AND TREATMENT OF PPI-RESISTANT ULCERS
    ASHIDA, K
    SAKAGUCHI, M
    TANAKA, M
    TAKIUCHI, H
    EGASHIRA, Y
    KATSU, K
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 20 : S67 - S71
  • [4] COMPARISON OF OMEPRAZOLE AND CIMETIDINE IN REFLUX ESOPHAGITIS - SYMPTOMATIC, ENDOSCOPIC, AND HISTOLOGICAL EVALUATIONS
    BATE, CM
    KEELING, PWN
    OMORAIN, C
    WILKINSON, SP
    FOSTER, DN
    MOUNTFORD, RA
    TEMPERLEY, JM
    HARVEY, RF
    THOMPSON, DG
    DAVIS, M
    FORGACS, IC
    BASSETT, KS
    RICHARDSON, PDI
    [J]. GUT, 1990, 31 (09) : 968 - 972
  • [5] PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN
    BERTILSSON, L
    LOU, YQ
    DU, YL
    LIU, Y
    KUANG, TY
    LIAO, XM
    WANG, KY
    REVIRIEGO, J
    ISELIUS, L
    SJOQVIST, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) : 388 - 397
  • [6] INTERETHNIC DIFFERENCE IN OMEPRAZOLES INHIBITION OF DIAZEPAM METABOLISM
    CARACO, Y
    TATEISHI, T
    WOOD, AJJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) : 62 - 72
  • [7] Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: Evidence from randomized clinical trials
    Caro, JJ
    Salas, M
    Ward, A
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (07) : 998 - 1017
  • [8] INTERPHENOTYPE DIFFERENCES IN DISPOSITION AND EFFECT ON GASTRIN-LEVELS OF OMEPRAZOLE - SUITABILITY OF OMEPRAZOLE AS A PROBE FOR CYP2C19
    CHANG, M
    TYBRING, G
    DAHL, ML
    GOTHARSON, E
    SAGAR, M
    SEENSALU, R
    BERTILSSON, L
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (05) : 511 - 518
  • [9] Csendes A, 1997, Dis Esophagus, V10, P38
  • [10] DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594